找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Optimal Use of Sandimmun in Endogenous Uveitis; D. BenEzra,R. B. Nussenblatt,P. Timonen Conference proceedings 1988Latest edition Sandoz L

[復(fù)制鏈接]
樓主: ARSON
11#
發(fā)表于 2025-3-23 10:45:35 | 只看該作者
12#
發(fā)表于 2025-3-23 14:16:02 | 只看該作者
results achieved so far with conventional therapy using systemic corticosteroids and cytotoxic agents, new treatment modalities have been sought. a) Start treatment with Sandimmun at initial doses of During the last four years, a total of over 300 patients 5 mg/kg/day. b) Use Sandimmun in combinatio
13#
發(fā)表于 2025-3-23 21:00:13 | 只看該作者
14#
發(fā)表于 2025-3-23 23:42:02 | 只看該作者
Present Experience with Sandimmun,ine, (97 patients) or placebo (12 patients). Most patients receiving Sandimmun had an initial loading dose of 5 to 10 mg/kg/day followed by a dose reduction according to ocular inflammatory activity and tolerability.
15#
發(fā)表于 2025-3-24 04:39:22 | 只看該作者
Introduction: Endogenous Uveitis, to the iris (iritis), the ciliary body (cyclitis) or both (iridocyclitis), the manifestation is coined anterior uveitis. Localization of the inflammatory reaction to the pars plana and peripheral fundus (pars planitis) as well as vitreous (vitritis) is coined intermediate uveitis, while posterior u
16#
發(fā)表于 2025-3-24 06:38:41 | 只看該作者
Conference proceedings 1988Latest editionndent studies all over the d) Taper Sandimmun dose as rapidly as possible to a world (over 200 patients) and in a masked manner in 4 maintenance dose below 5 mg/kg/day. e) Do not discontinue treatment with Sandimmun rap- independent controlled studies (over 100 patients re- idly.
17#
發(fā)表于 2025-3-24 12:24:38 | 只看該作者
18#
發(fā)表于 2025-3-24 15:51:40 | 只看該作者
19#
發(fā)表于 2025-3-24 20:32:39 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
20#
發(fā)表于 2025-3-25 00:38:40 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 14:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
汝阳县| 德化县| 科尔| 清丰县| 大渡口区| 昌邑市| 钦州市| 萝北县| 海阳市| 肃北| 吉安县| 青海省| 治多县| 南京市| 云林县| 新泰市| 武清区| 阳江市| 屏东市| 高密市| 黄大仙区| 信丰县| 银川市| 北票市| 西峡县| 雅安市| 西城区| 肇州县| 黎川县| 博罗县| 谢通门县| 和龙市| 旬阳县| 乌海市| 瓦房店市| 上林县| 大关县| 沧州市| 迁西县| 龙胜| 巧家县|